Some studies found the in vivo and ex vivo presence of survivin-reactive antibodies [148] and CTL clones restricted to several haplotypes [149,150,151], pointing out the immunologic properties of this protein and suggesting that survivin could be an attractive target for novel immunotherapies against cancer [97,152]. This evidence concerns the gene BIRC5 and cancer.